Evaluates seladelpar 10 mg vs. placebo for alkaline phosphatase normalization at 52 weeks
Patients enroll with alkaline phosphatase levels between 1- and 1.67-times upper limit of normal
Read more at prnewswire.comCymaBay Initiates IDEAL, a Phase 3 Placebo-Controlled, Randomized Study of Seladelpar in Patients with Primary Biliary Cholangitis and Incomplete Control of Alkaline Phosphatase
PR Newswire -
Thu Aug 10, 2023
Columnist
Contributor Content
Press Release
Sponsored Content
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
This article could contain syndicated content. We have not reviewed, approved, or endorsed the content and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/Alibaba%20by%20testing%20via%20Shutterstock.jpg)
